Combination Therapy With Anti-PD-1 or PD-1 Antibody Alone in Asian Pediatric Patients With Relapsed or Refractory Cancer
There is limited experience of PD-1 antibody combined with other therapies in children. We aimed to explore the antitumor activity and safety of PD-1 antibody monotherapy or combination with other regimens in relapsed or refractory pediatric cancer. This is a retrospective-case study conducted in tw...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-07-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2021.647733/full |
| _version_ | 1818907325670359040 |
|---|---|
| author | Yi Que Yi Que Juan Wang Juan Wang Jia Zhu Jia Zhu Na Li Junting Huang Junting Huang Suying Lu Suying Lu Feifei Sun Feifei Sun Lian Zhang Lian Zhang Zijun Zhen Zijun Zhen Li Zhang Li Zhang Ruiqing Cai Ruiqing Cai Haixia Guo Xiaofei Sun Xiaofei Sun Yizhuo Zhang Yizhuo Zhang |
| author_facet | Yi Que Yi Que Juan Wang Juan Wang Jia Zhu Jia Zhu Na Li Junting Huang Junting Huang Suying Lu Suying Lu Feifei Sun Feifei Sun Lian Zhang Lian Zhang Zijun Zhen Zijun Zhen Li Zhang Li Zhang Ruiqing Cai Ruiqing Cai Haixia Guo Xiaofei Sun Xiaofei Sun Yizhuo Zhang Yizhuo Zhang |
| author_sort | Yi Que |
| collection | DOAJ |
| description | There is limited experience of PD-1 antibody combined with other therapies in children. We aimed to explore the antitumor activity and safety of PD-1 antibody monotherapy or combination with other regimens in relapsed or refractory pediatric cancer. This is a retrospective-case study conducted in two Chinese expert centers. The primary objective of this study was to describe the overall response rate (ORR) and disease control rate (DCR). Secondary objectives included characterizing toxicities. Of the 22 pediatric patients with cancer who received PD-1 inhibitors, the median follow-up for all patients after the commencement of PD-1 therapy with or without other regimens was 12.3 months (0 - 43 months). PD-1 antibody monotherapy demonstrated antitumor activity in a population of pediatric patients with Hodgkin lymphoma (HL), with an objective response rate (ORR) and disease control rate (DCR) of 83.3% (3CR and 2PR) and 100%, respectively. However, no objective response was observed in patients with melanoma or Burkitt lymphoma evaluated in this study. We reviewed responses for patients with chemotherapy, decitabine or everolimus combination therapies with PD-1 antibodies, and found that PD-1 antibody combined with decitabine showed potential efficacy in pediatric patients with advanced embryonal rhabdomyosarcoma and lymphoepitheliomatoid-like carcinoma. There were no severe treatment-related adverse events (TRAEs) directly attributed to PD-1 antibody monotherapy in Asian pediatric patients with lower incidence of hematologic toxicity and nonhematologic toxicity. The Grade ≥3 TRAEs were attributed to the combination chemotherapy. |
| first_indexed | 2024-12-19T21:53:20Z |
| format | Article |
| id | doaj.art-8d2e05b04dd0406eb4dec0461ba79959 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-19T21:53:20Z |
| publishDate | 2021-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-8d2e05b04dd0406eb4dec0461ba799592022-12-21T20:04:21ZengFrontiers Media S.A.Frontiers in Immunology1664-32242021-07-011210.3389/fimmu.2021.647733647733Combination Therapy With Anti-PD-1 or PD-1 Antibody Alone in Asian Pediatric Patients With Relapsed or Refractory CancerYi Que0Yi Que1Juan Wang2Juan Wang3Jia Zhu4Jia Zhu5Na Li6Junting Huang7Junting Huang8Suying Lu9Suying Lu10Feifei Sun11Feifei Sun12Lian Zhang13Lian Zhang14Zijun Zhen15Zijun Zhen16Li Zhang17Li Zhang18Ruiqing Cai19Ruiqing Cai20Haixia Guo21Xiaofei Sun22Xiaofei Sun23Yizhuo Zhang24Yizhuo Zhang25Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, ChinaDepartment of Pediatric Oncology, Sun Yat-sen University Cancer Center, Guangzhou, ChinaSun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, ChinaDepartment of Pediatric Oncology, Sun Yat-sen University Cancer Center, Guangzhou, ChinaSun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, ChinaDepartment of Pediatric Oncology, Sun Yat-sen University Cancer Center, Guangzhou, ChinaDepartment of Pediatrics, Nanfang Hospital, Southern Medical University, Guangzhou, ChinaSun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, ChinaDepartment of Pediatric Oncology, Sun Yat-sen University Cancer Center, Guangzhou, ChinaSun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, ChinaDepartment of Pediatric Oncology, Sun Yat-sen University Cancer Center, Guangzhou, ChinaSun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, ChinaDepartment of Pediatric Oncology, Sun Yat-sen University Cancer Center, Guangzhou, ChinaSun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, ChinaDepartment of Pediatric Oncology, Sun Yat-sen University Cancer Center, Guangzhou, ChinaSun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, ChinaDepartment of Pediatric Oncology, Sun Yat-sen University Cancer Center, Guangzhou, ChinaSun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, ChinaDepartment of Pediatric Oncology, Sun Yat-sen University Cancer Center, Guangzhou, ChinaSun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, ChinaDepartment of Pediatric Oncology, Sun Yat-sen University Cancer Center, Guangzhou, ChinaDepartment of Pediatrics, Nanfang Hospital, Southern Medical University, Guangzhou, ChinaSun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, ChinaDepartment of Pediatric Oncology, Sun Yat-sen University Cancer Center, Guangzhou, ChinaSun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, ChinaDepartment of Pediatric Oncology, Sun Yat-sen University Cancer Center, Guangzhou, ChinaThere is limited experience of PD-1 antibody combined with other therapies in children. We aimed to explore the antitumor activity and safety of PD-1 antibody monotherapy or combination with other regimens in relapsed or refractory pediatric cancer. This is a retrospective-case study conducted in two Chinese expert centers. The primary objective of this study was to describe the overall response rate (ORR) and disease control rate (DCR). Secondary objectives included characterizing toxicities. Of the 22 pediatric patients with cancer who received PD-1 inhibitors, the median follow-up for all patients after the commencement of PD-1 therapy with or without other regimens was 12.3 months (0 - 43 months). PD-1 antibody monotherapy demonstrated antitumor activity in a population of pediatric patients with Hodgkin lymphoma (HL), with an objective response rate (ORR) and disease control rate (DCR) of 83.3% (3CR and 2PR) and 100%, respectively. However, no objective response was observed in patients with melanoma or Burkitt lymphoma evaluated in this study. We reviewed responses for patients with chemotherapy, decitabine or everolimus combination therapies with PD-1 antibodies, and found that PD-1 antibody combined with decitabine showed potential efficacy in pediatric patients with advanced embryonal rhabdomyosarcoma and lymphoepitheliomatoid-like carcinoma. There were no severe treatment-related adverse events (TRAEs) directly attributed to PD-1 antibody monotherapy in Asian pediatric patients with lower incidence of hematologic toxicity and nonhematologic toxicity. The Grade ≥3 TRAEs were attributed to the combination chemotherapy.https://www.frontiersin.org/articles/10.3389/fimmu.2021.647733/fullPD-1 antibodypediatric cancermonotherapycombinationPD-L1 |
| spellingShingle | Yi Que Yi Que Juan Wang Juan Wang Jia Zhu Jia Zhu Na Li Junting Huang Junting Huang Suying Lu Suying Lu Feifei Sun Feifei Sun Lian Zhang Lian Zhang Zijun Zhen Zijun Zhen Li Zhang Li Zhang Ruiqing Cai Ruiqing Cai Haixia Guo Xiaofei Sun Xiaofei Sun Yizhuo Zhang Yizhuo Zhang Combination Therapy With Anti-PD-1 or PD-1 Antibody Alone in Asian Pediatric Patients With Relapsed or Refractory Cancer Frontiers in Immunology PD-1 antibody pediatric cancer monotherapy combination PD-L1 |
| title | Combination Therapy With Anti-PD-1 or PD-1 Antibody Alone in Asian Pediatric Patients With Relapsed or Refractory Cancer |
| title_full | Combination Therapy With Anti-PD-1 or PD-1 Antibody Alone in Asian Pediatric Patients With Relapsed or Refractory Cancer |
| title_fullStr | Combination Therapy With Anti-PD-1 or PD-1 Antibody Alone in Asian Pediatric Patients With Relapsed or Refractory Cancer |
| title_full_unstemmed | Combination Therapy With Anti-PD-1 or PD-1 Antibody Alone in Asian Pediatric Patients With Relapsed or Refractory Cancer |
| title_short | Combination Therapy With Anti-PD-1 or PD-1 Antibody Alone in Asian Pediatric Patients With Relapsed or Refractory Cancer |
| title_sort | combination therapy with anti pd 1 or pd 1 antibody alone in asian pediatric patients with relapsed or refractory cancer |
| topic | PD-1 antibody pediatric cancer monotherapy combination PD-L1 |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2021.647733/full |
| work_keys_str_mv | AT yique combinationtherapywithantipd1orpd1antibodyaloneinasianpediatricpatientswithrelapsedorrefractorycancer AT yique combinationtherapywithantipd1orpd1antibodyaloneinasianpediatricpatientswithrelapsedorrefractorycancer AT juanwang combinationtherapywithantipd1orpd1antibodyaloneinasianpediatricpatientswithrelapsedorrefractorycancer AT juanwang combinationtherapywithantipd1orpd1antibodyaloneinasianpediatricpatientswithrelapsedorrefractorycancer AT jiazhu combinationtherapywithantipd1orpd1antibodyaloneinasianpediatricpatientswithrelapsedorrefractorycancer AT jiazhu combinationtherapywithantipd1orpd1antibodyaloneinasianpediatricpatientswithrelapsedorrefractorycancer AT nali combinationtherapywithantipd1orpd1antibodyaloneinasianpediatricpatientswithrelapsedorrefractorycancer AT juntinghuang combinationtherapywithantipd1orpd1antibodyaloneinasianpediatricpatientswithrelapsedorrefractorycancer AT juntinghuang combinationtherapywithantipd1orpd1antibodyaloneinasianpediatricpatientswithrelapsedorrefractorycancer AT suyinglu combinationtherapywithantipd1orpd1antibodyaloneinasianpediatricpatientswithrelapsedorrefractorycancer AT suyinglu combinationtherapywithantipd1orpd1antibodyaloneinasianpediatricpatientswithrelapsedorrefractorycancer AT feifeisun combinationtherapywithantipd1orpd1antibodyaloneinasianpediatricpatientswithrelapsedorrefractorycancer AT feifeisun combinationtherapywithantipd1orpd1antibodyaloneinasianpediatricpatientswithrelapsedorrefractorycancer AT lianzhang combinationtherapywithantipd1orpd1antibodyaloneinasianpediatricpatientswithrelapsedorrefractorycancer AT lianzhang combinationtherapywithantipd1orpd1antibodyaloneinasianpediatricpatientswithrelapsedorrefractorycancer AT zijunzhen combinationtherapywithantipd1orpd1antibodyaloneinasianpediatricpatientswithrelapsedorrefractorycancer AT zijunzhen combinationtherapywithantipd1orpd1antibodyaloneinasianpediatricpatientswithrelapsedorrefractorycancer AT lizhang combinationtherapywithantipd1orpd1antibodyaloneinasianpediatricpatientswithrelapsedorrefractorycancer AT lizhang combinationtherapywithantipd1orpd1antibodyaloneinasianpediatricpatientswithrelapsedorrefractorycancer AT ruiqingcai combinationtherapywithantipd1orpd1antibodyaloneinasianpediatricpatientswithrelapsedorrefractorycancer AT ruiqingcai combinationtherapywithantipd1orpd1antibodyaloneinasianpediatricpatientswithrelapsedorrefractorycancer AT haixiaguo combinationtherapywithantipd1orpd1antibodyaloneinasianpediatricpatientswithrelapsedorrefractorycancer AT xiaofeisun combinationtherapywithantipd1orpd1antibodyaloneinasianpediatricpatientswithrelapsedorrefractorycancer AT xiaofeisun combinationtherapywithantipd1orpd1antibodyaloneinasianpediatricpatientswithrelapsedorrefractorycancer AT yizhuozhang combinationtherapywithantipd1orpd1antibodyaloneinasianpediatricpatientswithrelapsedorrefractorycancer AT yizhuozhang combinationtherapywithantipd1orpd1antibodyaloneinasianpediatricpatientswithrelapsedorrefractorycancer |